Results 121 to 130 of about 1,835 (190)

Emerging non-D₂ receptor-based therapies for schizophrenia: a focus on muscarinic and glutamatergic pathways. [PDF]

Front Psychiatry
Wang Y, Wang J, Zhang X, Liu X.
europepmc   +1 more source

Trace amine-associated receptor 1 agonists differentially regulate dopamine transporter function. [PDF]

Mol Pharmacol
Huey JK, Shi X, Schutzer WE, Janowsky A, Abbas AI.   +4 more
europepmc   +1 more source

Trace Amine-associated Receptor 1: Role in the Implementation of Neuroprotective Signaling Pathways. [PDF]

Int J Mol Cell Med
Voevoda M, Filimonov D, Knyazev R, Ishchenko R, Eresko A, Trubnikova N, Belotserkovskaya M, Kisilenko I, Nosova I, Solopov M.   +9 more
europepmc   +1 more source

Improving AlphaFold2 Performance in Virtual Screens Targeting GPCRs by Enhancing Binding-Site Conformational Sampling. [PDF]

J Chem Inf Model
Mitjavila-Domènech N, Díaz-Holguín A, Hu H, Kahlous NA, Cabeza de Vaca I, Wallner B, Carlsson J.   +6 more
europepmc   +1 more source

Editorial: Psychedelic substances and neurological diseases: from basics to clinical application. [PDF]

Front Pharmacol
Linardi A, Caetano AL, Ureshino RP.
europepmc   +1 more source

Receptor interaction profiles of 4-alkoxy-2,6-dimethoxyphenethylamines (Ψ derivatives) and related amphetamines. [PDF]

Front Pharmacol
Kolaczynska KE, Trachsel D, Hoener MC, Liechti ME, Luethi D.   +4 more
europepmc   +1 more source

Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders. [PDF]

Clin Pharmacol
Aribindi K, Shende TC, Albertson TE.
europepmc   +1 more source

From Stress to Neurodegeneration: A New Look at the Pathogenesis of Parkinson's Disease. [PDF]

Biomedicines
Kazanskaya RB, Tsytsarev V, Volnova AB, Gainetdinov RR, Lopachev AV.   +4 more
europepmc   +1 more source